Oxypurinol protects renal ischemia/reperfusion injury via heme oxygenase-1 induction [PDF]
Frontiers in Medicine, 2023 Renal ischemia/reperfusion (I/R) injury is a major cause of acute kidney injury (AKI) by increasing oxidative stress, inflammatory responses, and tubular cell death.
Hye Bin Kang +3 more
doaj +6 more sources
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics [PDF]
Clinical and Translational Science, 2023 The genetic determinants of the allopurinol dose‐concentration relationship have not been extensively studied. We aimed to clarify what factors, including genetic variation in urate transporters, influence oxypurinol pharmacokinetics (PKs).
Hailemichael Z. Hishe +6 more
doaj +6 more sources
Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate‐Lowering Response—In Search of a Minimum Effective Oxypurinol Concentration [PDF]
Clinical and Translational Science, 2020 The aims of this study were to determine factors that predict serum urate (SU) lowering response to allopurinol and the conversion of allopurinol to oxypurinol, and to determine a minimum therapeutic oxypurinol concentration.
Lisa K. Stamp +8 more
doaj +4 more sources
Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males [PDF]
Clinical and Translational Science, 2023 Females present a higher risk of adverse drug reactions. Sex‐related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical trials.
Jessica Hindi +13 more
doaj +4 more sources
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics [PDF]
Clinical and Translational Science, 2021 The missense variant, breast cancer resistance protein (BCRP) p.Q141K, which encodes a reduced function BCRP, has been linked to poor response to allopurinol.
Bianca Vora +6 more
doaj +2 more sources
Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia. [PDF]
PLoS ONE, 2012 Cancer cachexia is a wasting condition, driven by systemic inflammation and oxidative stress. This study investigated eicosapentaenoic acid (EPA) in combination with oxypurinol as a treatment in a mouse model of cancer cachexia. Mice with cancer cachexia
Vanessa C Vaughan +4 more
doaj +3 more sources
Enhanced and Sustained Transdermal Delivery of Oxypurinol Using Thermosensitive Gel Combined with Polymeric Solid Microneedles [PDF]
ACS OmegaSiti Nur Fatimah S. Mohamad +10 more
doaj +3 more sources
PLoS ONE, 2019 A fixed dose combination of lesinurad and allopurinol has been recently approved by USFDA and EMA for treatment of gout-associated hyperuricemia in patients who have not achieved target serum uric acid levels with allopurinol alone.
Muzaffar Iqbal +3 more
doaj +3 more sources
Allopurinol non-covalently facilitates binding of unconventional peptides to HLA-B*58:01 [PDF]
Scientific Reports, 2023 Allopurinol, widely used in gout treatment, is the most common cause of severe cutaneous adverse drug reactions. The risk of developing such life-threatening reactions is increased particularly for HLA-B*58:01 positive individuals.
Xuelu Huan +3 more
doaj +2 more sources
Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase. [PDF]
J Biol Chem, 2023 Sekine M +6 more
europepmc +3 more sources